Summary
- Harmony Biosciences has filed to raise $100 million in an IPO, although the final figure will likely differ.
- The firm is commercializing an in-licensed drug to treat various forms of narcolepsy.
- HRMY has produced sharp sales growth from a zero revenue base as it ramps up commercialization efforts.
- Looking for more stock ideas like this one? Get them exclusively at IPO Edge. Get started today »
Quick Take
Harmony Biosciences Holdings (HRMY) has filed to raise $100 million in an IPO of its common stock, according to an S-1 registration statement.
The firm is a biopharma commercializing its WAKIX molecule for the treatment of excessive sleepiness in adult narcolepsy.
HRMY has initially grown revenue quickly as it begins to commercialize its primary product.
I’ll provide an update when we learn more about the IPO from management.
Company & Technology
Plymouth Meeting, Pennsylvania-based Harmony was founded to commercialize a drug to treat narcolepsy that is not scheduled as a controlled substance.
Management is headed by president and Chief Executive Officer John Jacobs, who has been with the firm since October 2017 and was previously SVP and General Manager of the Respiratory Business Unit at Teva Pharmaceuticals (TEVA).
Below is a brief overview video of narcolepsy:
